Post-Macugen, Still In-Licensing to Uncover Value in Ophthalmology
• By Chris Morrison
The lesson that entrepreneurs and VCs seem to be taking from the fast-paced ophthalmology sector is the need for shorter development time frames and clinical candidates with reduced risk. Among others, MacuSight, Danube, and Lux, profiled here, are to one extent or another revisiting the existing pharmacopeia to test ophthalmic indications for existing compounds.
Blink, and you may miss it.
The ophthalmology field is moving fast. For evidence, look no further than Genentech Inc. 's recently approved ranibizumab (Lucentis)...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.